Presentation is loading. Please wait.

Presentation is loading. Please wait.

TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1

Published byAndrea Washington Modified over 6 years ago

Similar presentations

Presentation on theme: "TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1"— Presentation transcript:

1 TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1
ARV-trial.com TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1 Design No randomisation Open-label W12 W24 GT1a, no cirrhosis OBV/PTV/r + DSV + RBV SVR12 > 18 years HCV infection, genotype 1 HCV RNA > 1,000 IU/ml Naïve or pre-treated with IFN or PEG-IFN + RBV With or without compensated cirrhosis GT1a, cirrhosis OBV/PTV/r + DSV + RBV SVR12 GT1b, no cirrhosis OBV/PTV/r + DSV SVR12 GT1b, cirrhosis OBV/PTV/r + DSV + RBV SVR12 Treatment regimens Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r): 25/150/100 mg qd = 2 tablets Dasabuvir (DSV): 250 mg bid RBV: or mg/day in 2 doses according to body weight (< or > 75 kg) Objective SVR12 (HCV RNA <15 IU/ml), with 95% CI, by ITT, descriptive analysis TOPAZ-II Neau R. AASLD 2015, Abs. 1065 1

2 TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1
ARV-trial.com TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1 Baseline characteristics OBV/PTV/r + DSV + RBV N = 615 Mean age, years 55 Female 36% White / Black 85% / 14% Genotype 1a / 1b, n 451 / 163 HCV RNA, log10 IU/ml, mean 6.0 Fibrosis stage : F0-F1/ F2 / F3 / F4 49% / 14% / 18% / 19% IL28B CC genotype 24% Naïve 71% Prior treatment with IFN or PEG-IFN + RBV Intolerant Non response Breakthrough/relapse 29% 21% 45% 34% TOPAZ-II Neau R. AASLD 2015, Abs. 1065 2

3 TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1
SVR12, % (ITT) % 96 98 98 97 96 96 96 100 95 93 95 95 95 92 80 60 40 20 615 437 178 452 163 134 481 146 467 304 88 108 115 Naïve Experienced GT1a GT1b < > CC Non-CC F0-F1 F2 F3 F4 Overall ITT Prior treatment experience Genotype HCV RNA IU/ml IL28B genotype Fibrosis stage TOPAZ-II Neau R. AASLD 2015, Abs. 1065

4 TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1
SVR12, % (mITT*) 20 40 60 80 100 97 98 95 99 96 602 428 174 Naïve Experienced GT1a GT1b < > CC Non-CC F0-F1 F3 F4 IL28B genotype Fibrosis stage HCV RNA IU/m Genotype Prior treatment experience Overall ITT 441 161 131 471 144 456 297 87 107 111 F2 % * Sensitivity analysis excluding excluding patients lost to follow-up and patients that prematurely discontinued study drug with no on-treatment virologic failure TOPAZ-II Neau R. AASLD 2015, Abs. 1065

5 TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1
Patients not achieving SVR12 (ITT population) Reasons for non-response n/N (%) Virologic failure 16/615 (2.6%) Breakthrough 5/615 (0.8%) Relapse (by post-treatment W12) 11/590 (1.9%) Premature discontinuation* 3/615 (0.5%) Missing SVR12 data 10/615 (1.6%) *2 patients discontinued due to an adverse event ; 1 patient withdrew consent TOPAZ-II Neau R. AASLD 2015, Abs. 1065

6 TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1
ARV-trial.com TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1 Treatment emerging adverse events and laboratory abnormalities, N (%) OBV/PTV/r + DSV + RBV, N = 615 Serious adverse event 4% Discontinuation for adverse event 6 (1%) ** Adverse event leading to RBV dose reduction 73 (12%) Fatal adverse event 1 (0.2%) ** Adverse event in ≥ 10% of patients Fatigue 32% Nausea 16% Headache Pruritus 13% Insomnia Hemoglobin Grade 2 : 8-10 g/dl Grade 3 : g/dl 6% 0.3% ALT : grade 3 (5-20 x ULN) / grade 4 (> 20 x ULN) 4 (0.7%) / 1 (0.2%) AST : grade 3 (5-20 x ULN) / grade 4 3 (0.5%) / 0 Total bilirubin : grade 3 (3-10 x ULN) / grade 4 3% / 0.2% * Nausea (N = 2), fatigue (N = 1), lethargy/vomiting (N = 1), hypercortisolism (N = 1), peritonitis (N = 1) ** Death due to metastatic pancreatic adenocarcinoma (Stage IV). Unrelated to HCV therapy TOPAZ-II Neau R. AASLD 2015, Abs. 1065 6

7 TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1
Summary In the TOPAZ-II study, treatment-naïve or -experienced patients with HCV genotype 1 infection with or without cirrhosis achieved high SVR12 rates (95.3% in the ITT population and 97.3% in the mITT population) with 12- or 24-weeks of treatment with OBV/PTV/r + DSV ± RBV Treatment was well tolerated with low rates of serious adverse events and study drug discontinuations due to adverse events TOPAZ-II Neau R. AASLD 2015, Abs. 1065

Download ppt "TOPAZ-II Study: OBV/PTV/r + DSV + RBV for genotype 1"

Similar presentations

OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind 18-70 years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.

OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label 18-70 years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV + placebo Randomisation* Partial blind 18-70 years Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 10,000.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV + placebo Randomisation* Partial blind years Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 10,000.
OBV/PTV/r Placebo Randomisation** 2 : 1 18-75 years Chronic HCV Genotype 1b HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated, no prior failure with DAA Without.

OBV/PTV/r Placebo Randomisation** 2 : years Chronic HCV Genotype 1b HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated, no prior failure with DAA Without.
 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg bid  Objective.

 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg bid  Objective.
TURQUOISE-I OBV/PTV/r + DSV + RBV Randomisation* 1 : 1 Open-label 18-70 years HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated with PEG-IFN +

TURQUOISE-I OBV/PTV/r + DSV + RBV Randomisation* 1 : 1 Open-label years HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated with PEG-IFN +
 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg BID –RBV.

 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg BID –RBV.
No randomization N = 59 W12W24 Arm B : compensated cirrhosis N = 31 N = 29 Arm C : compensated cirrhosis Arm A : No cirrhosis AGATE-II Study: OBV/PTV/r.

No randomization N = 59 W12W24 Arm B : compensated cirrhosis N = 31 N = 29 Arm C : compensated cirrhosis Arm A : No cirrhosis AGATE-II Study: OBV/PTV/r.
> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.

> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.
Asselah T. AASLD 2015, Abs. 714 Randomisation 1:1 Open-label 18-65 years HCV genotype 4 HCV RNA ≥ 1,000 IU/ml Naïve or pre-treated with PEG-IFN + RBV (Part.

Asselah T. AASLD 2015, Abs. 714 Randomisation 1:1 Open-label years HCV genotype 4 HCV RNA ≥ 1,000 IU/ml Naïve or pre-treated with PEG-IFN + RBV (Part.
OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.

OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.
No randomisation Open-label 18-70 years HCV genotype 1 Naïve or null-response to PEG-IFN + RBV HCV RNA > 10,000 IU/ml No cirrhosis No HBV or HIV co-infection.

No randomisation Open-label years HCV genotype 1 Naïve or null-response to PEG-IFN + RBV HCV RNA > 10,000 IU/ml No cirrhosis No HBV or HIV co-infection.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.
SAPPHIRE-I Feld JJ. NEJM 2014;370:1594-1603 SAPPHIRE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for genotype 1  Treatment regimens.

SAPPHIRE-I Feld JJ. NEJM 2014;370: SAPPHIRE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for genotype 1  Treatment regimens.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, by ITT, descriptive analysis OBV/PTV/r + DSV + RBV No randomisation Open-label CORAL-I Study cohort.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, by ITT, descriptive analysis OBV/PTV/r + DSV + RBV No randomisation Open-label CORAL-I Study cohort.
SOF/VEL 400/100 mg qd N = 120 W12 SOF + RBV > 18 years Chronic HCV infection Genotype 2 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis.

SOF/VEL 400/100 mg qd N = 120 W12 SOF + RBV > 18 years Chronic HCV infection Genotype 2 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + DSV + SOF +RBV Open-label W24 ≥ 18 years Chronic HCV Genotype 1 Prior failure on DAA-regimen.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + DSV + SOF +RBV Open-label W24 ≥ 18 years Chronic HCV Genotype 1 Prior failure on DAA-regimen.
Dore G. J Hepatol 2016; 64:19-28 MALACHITE TVR + PEG-IFN + RBV Randomisation Open-label 18-65 years HCV genotype 1 HCV RNA > 10,000 IU/ml Naïve (MALACHITE-I)

Dore G. J Hepatol 2016; 64:19-28 MALACHITE TVR + PEG-IFN + RBV Randomisation Open-label years HCV genotype 1 HCV RNA > 10,000 IU/ml Naïve (MALACHITE-I)
Poordad F. NEJM 2014;368:45-53 2D Phase IIa  Design  Treatment regimens – Paritaprevir/rironavir (PTV/r) : PTV 250 or 150 mg qd/ritonavir 100 mg qd (2.

Poordad F. NEJM 2014;368: D Phase IIa  Design  Treatment regimens – Paritaprevir/rironavir (PTV/r) : PTV 250 or 150 mg qd/ritonavir 100 mg qd (2.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.

Similar presentations

Ads by Google